retinal disease

News

Belite plans filing for oral Stargardt drug after phase 3 wi...

The first therapy for sight-robbing Stargardt disease could be on the way, as Belite Bio's tinlarebant hits the mark in a phase 3 trial.

News

Downward market trajectory in black bar chart

Outlook blindsided as FDA blocks wet AMD drug once again

Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.

News

SpliceBio chief executive Miquel Vila-Perelló

SpliceBio gathers $135m for eye disease gene therapies

Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.

Patients

The burden of diabetic vision loss in the West

Vision loss associated with diabetes is one of the more prevalent and growing healthcare burdens in the Western world.

News

FDA clears Roche’s Vabysmo for retinal vein occlusion

Roche has claimed a third approval from the FDA for its eye disease therapy Vabysmo – already its fastest-growing product – that could make it an option for hundreds of th

News

FDA kicks off review of Roche’s Vabysmo in RVO

Roche could be just months away from a third indication for its eye drug Vabysmo that could accelerate its already fast growth in the US.

Belite plans filing for oral Stargardt drug after phase 3 wi...

Outlook blindsided as FDA blocks wet AMD drug once again

SpliceBio gathers $135m for eye disease gene therapies

The burden of diabetic vision loss in the West

FDA clears Roche’s Vabysmo for retinal vein occlusion

FDA kicks off review of Roche’s Vabysmo in RVO

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

retinal disease

Editor's Picks